Advertisement
Advertisement
Zynlonta

Zynlonta

Manufacturer:

BSP Pharmaceuticals
Concise Prescribing Info
Contents
Loncastuximab tesirine

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.
Indications/Uses
Relapsed or refractory diffuse large B-cell lymphoma in adult patients after ≥2 lines of systemic therapy.
Dosage/Direction for Use
IV 0.15 mg/kg infusion over 30 min every 3 wk for 2 cycles. 0.075 mg/kg infusion over 30 min every 3 wk for subsequent cycles. Premed: Administer dexamethasone 4 mg PO or IV bd for 3 days beginning the day before Zynlonta administration. If dexamethasone does not begin the day before Zynlonta, administer dexamethasone at least 2 hr prior to Zynlonta.
MIMS Class
Targeted Cancer Therapy
ATC Classification
L01FX22 - loncastuximab tesirine ; Belongs to the class of other monoclonal antibodies and antibody drug conjugates. Used in the treatment of cancer.
Presentation/Packing
Form
Zynlonta powd for soln for inj 10 mg
Packing/Price
1's
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement